Clinical Report: Variability in Clinical Trial Enrollment for Patients with Advanced Cancer
Background
Clinical trials are essential for advancing oncology treatments, yet enrollment rates are critically low, with less than 10% of patients with advanced cancer participating. This shortfall limits the generalizability of trial results and equitable access to potentially life-saving innovations.
Data Highlights
The study analyzed a national cohort of over 200,000 patients with advanced cancer, utilizing the US Flatiron Health Research Database to assess trial participation rates and associated delivery system factors.
Key Findings
Most patients with advanced cancer express a willingness to participate in clinical trials when discussed by their oncologist.
Enrollment rates in the US remain below 10%, with significant variation across different practices and physicians.
Physician and practice-level factors account for more variability in trial participation than patient-level characteristics.
Identifying 'super enrollers' can help understand effective practices.
The study highlights the need for structural reforms in clinical delivery systems.
Clinical Implications
Healthcare providers should recognize their pivotal role in facilitating clinical trial discussions with patients. Addressing practice-level barriers and enhancing infrastructure may improve enrollment rates and ensure broader access to innovative therapies.
Conclusion
The findings underscore the importance of understanding the variability in clinical trial enrollment at the physician and practice levels to enhance patient access to clinical research opportunities.
